My aim is to develop a multidisciplinary approach and a translational research in organ transplantation, based on the connection of immunological, histological, molecular and clinical knowledge.
This approach will allow us to understand and identify new relevant diseases, refine diagnosis and staging of diseases and stratify the risk of graft loss. These lessons will open a new understanding of transplant failures. My research interests are focused on a major turning point in the field of transplantation, the pivotal role of the alloantibody response in clinical transplantation, the mechanisms of action of these antibodies and the development of specific therapies of antibody-mediated rejection in transplant populations.
Even if my work is focused on the human model of kidney transplantation, these notions go far beyond renal grafts and I aim to integrate information of the alloimmune response in the fields of heart and lung transplantations.
Beginning 5 yrs ago, I have worked in the Immulogy-Therapeutic Targets INSERM UMR-S-940 and Jean Dausset laboratories on the clinical relevance of anti-HLA antibodies in kidney transplantation. I have developed an important network, including national and international collaborations (Tissue Typing Laboratory, University of Pittsburgh Medical Center ; Laboratory of Transplant Applied Genomic Center. University of Alberta, Edmonton).
We constructed a national database network approved by the National French Commission for bioinformatics including seven French transplant centers (DIVAT, Données Informatisées VAlidées en Transplantation). This permitted my colleagues and I to describe new distinct and clinical relevant patterns of rejection, such as antibody-mediated vascular rejection or subclinical antibody-mediated rejection. More generally, our data support in a human model the notion of immunologic damage demonstrated in murine models.
The identification of antibody-mediated vascular rejection points out thinking toward the more general concept of vascular damage and immune accelerated arteriosclerosis. We have also provided concrete information regarding the stratification of immunological risk in kidney transplantation, post transplant specific immunossupression therapies and treatment of allograft rejections. The antibody-targeting treatment we proposed is now recognized by FDA as the gold standard therapy for antibody-mediated rejection and worldwide use in medical practice.